Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 67Other hematologic neoplasm 10Lymphoid 10Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Other 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 390pembrolizumab 325Prednisone 284Gemcitabine 273enzalutamide 254Radiotherapy 251Nivolumab 247Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 197Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 98cabozantinib 97abiraterone 97Sorafenib 97atezolizumab 96Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × isatuximab × Genitourinary × Clear all
NCT03367819 2022-05-16

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Sanofi

Phase 1/2 Terminated
44 enrolled 24 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡